: iStockAnalyst.com Symbols Feed

Earnings News : EXPE, NEM, FTE, FSLR, CVX, AEP, ODP, XRAY, MCO, ORLY, AGN, SII, APA, PNW, PPL, WMGI, MWW, IRM, DNB

Fri, 30 Oct 2009 19:47:00 GMT

Expedia’s (EXPE) third quarter earnings beat the Zacks Consensus Estimate by 15 cents. Revenue beat by 2.8%.[More...]

Daily Highlights: 10/26/09

Mon, 26 Oct 2009 13:02:47 GMT

Asian shares were mostly higher Monday with S.Korean shares helped by upbeat economics.Bank failures in US exceed 100 for this year, most closings since 1992.China's September coal imports increase 7% from August as economy recoversOil prices slipped to near $80 a barrel in AsiaDollar falls versus Euro as recovery signs, stock gains sap safety demand.Japan to punish BNP Paribas's unit over convertible bond, share price manipulation.Japan's PM Hatoyama says recovery 'unpredictable,’ unemployment may worsen.S Korea's Q3 GDP rises 2.9% - fastest quarterly pace in more than seven years.SEC considering filing securities fraud charges against ICAP's US subsidiary.[More...]

Allergan Sues FDA (NYSE: AGN)

Mon, 05 Oct 2009 13:51:39 GMT

One of the well known makers of the Botox wrinkle treatment, Allergan Inc, has gathered its courage and challenged the government's ban on off-label drug marketing to doctors.[More...]

Financially Healthy Stocks With Attractive Valuations

Thu, 20 Aug 2009 18:56:39 GMT

Value Expectations teaches professional investors how to make more informed investment decision evaluating stocks on the basis of corporate performance, valuation, management quality, earnings quality, and other proprietary variables. These variables inevitably help identify companies that are potential long-term investments while avoiding potential torpedoes. However, during the financial crisis, leverage and a week balance sheet played a significant part when investors evaluated a holding. To help our institutional clients navigate the environment The Applied Finance Group (AFG) developed the risk analysis template specifically to model the healthiness of a company’s balance sheet. In addition to the risk analysis template we also developed a template that calculated an Altman Z-Score developed to identify companies that are most likely to go bankrupt. As professional[More...]

New Indexes To Track Healthcare Trends And More

Wed, 05 Aug 2009 15:34:05 GMT

Below are links and descriptions for 23 new stock indexes I have created, revised, and tracked over the past few years which are now featured at a new website called Investars YOU. The new site includes automated index tracking, allows investors to create custom stock portfolios based on their individual preferences, and now features free access to all of the component stocks in each of my indexes. Some of the top performing stocks from my healthcare indexes on a year-to-date basis (...)[More...]

Paired Trade: Buy Hormel, Sell DineEquity

Fri, 10 Jul 2009 00:09:39 GMT

This is the 7th in a series of ideas where I contrast a cheap security with an expensive one that otherwise shares some characteristics. So far, I am 5 for 6: [More...]

Spectrum Pharma (NASDAQ:SPPI): Undervalued Based On Late-Stage Pipeline

Fri, 19 Jun 2009 16:45:08 GMT

With two potential approvals coming up in the next 120 days, Spectrum Pharmaceuticals (Nasdaq: SPPI) still remains a hidden gem. Investor's Business Daily bases its rankings on the relationship that one company has with other companies within the same industry. In my June 12 article, I indicated the company could likely generate $280 million in annual revenue within the next 12-18 months upon approval of both the company's cancer drugs Zevalin and Fusilev. The table below is a lis (...)[More...]

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Fri, 29 May 2009 12:08:55 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

Allergan Battling Challenges Well

Thu, 28 May 2009 21:27:12 GMT

Botox Approval for Spasticity Delayed, But Fundamentals Remain Strong From a fundamental standpoint, we are enthusiastic about the future of Allergan, Inc. (AGN). Although the company is facing significant challenges in the form of slowing sales due to the global economic weakness, safety issues surrounding the use of Botox and foreign currency headwinds, we think Allergan will be able to face these challenges well and will be back on its historical mid-to-high teens earnings growth trajectory starting in 2011. We consider Allergan to be one of the premier specialty pharmaceutical companies in the world. The company possesses a strong blockbuster product in Botox and a slew of innovative new products in the[More...]

Inspire reports $8.5 million 3Q loss

Fri, 06 Nov 2009 17:48:00 GMT

Nov. 6--DURHAM -- Inspire Pharmaceuticals Inc. on Thursday reported a loss of $8.5 million for the third quarter, mostly owing to an increase in expenses even as revenues for the company's lead products rose.
Operating expenses for the third quarter totaled $33.1 million, up from $29 million a year ago, primarily because of higher research and development expenses, including a $3.3 million milestone payment to Yamasa Corp. for a technology agreement to enable a two-supplier strategy for denufosol, the company's candidate for treating cystic fibrosis.
Revenue from Azasite, the company's candidate for treating pinkeye, was $9.0 million, nearly double the $4.7 million from the third quarter of 2008.

: iStockAnalyst.com Symbols Feed

Earnings News : EXPE, NEM, FTE, FSLR, CVX, AEP, ODP, XRAY, MCO, ORLY, AGN, SII, APA, PNW, PPL, WMGI, MWW, IRM, DNB

Daily Highlights: 10/26/09

Allergan Sues FDA (NYSE: AGN)

Financially Healthy Stocks With Attractive Valuations

New Indexes To Track Healthcare Trends And More

Paired Trade: Buy Hormel, Sell DineEquity

Spectrum Pharma (NASDAQ:SPPI): Undervalued Based On Late-Stage Pipeline

FDA, Clinical Trial Updates: JNJ, INCY, MEDX, CYTX, AGN, PPHM

Allergan Battling Challenges Well

Inspire reports $8.5 million 3Q loss

Allergan Wins Patent Infringement Lawsuit Against Exela and Apotex

Allergan Q2 Net Earnings Up

FDA orders botulinum toxin warnings

Correction: Allergan story

Jobless Claims Tally Highest Since 1982

Jobless Rate Still Up; Sales Still Weak

Botox Sales Sag, Surprising Maker Allergan Thought Recession Wouldn't Affect Wrinkle Shots

More sour economic reports for employment, retail

THE READ: ; Morgantown Has Nation's Lowest Jobless Rate

Spectrum Pharmaceuticals Announces Third Quarter 2009 Corporate Update; ZEVALIN® Sales up 80% over Third Quarter 2008

Phase Forward Reports Third Quarter 2009 Results

Allergan Announces Victory in Brimonidine Patent Infringement Case

Licensing Executives Society Announces 2009 Deals of Distinction Awards

SYSPRO Honored for Business Excellence

BenchmarkJournal.Com Free Analyst Review for ACN, CHL, L, AGN, BA and AMX

Spectrum Pharmaceuticals Announces Second Quarter 2009 Corporate Update

StockPreacher.com issues Trading Outlook for Spectrum Pharmaceuticals Inc.

StreetInvesting.Com Free Research on AGN, DAL, CYH, GNA, JBL and DT

Allergan Reports Second Quarter 2009 Operating Results

Form 4 ALLERGAN INC For: Nov 30 Filed by: INGRAM ROBERT ALEXANDER (10K)

Form 4 ALLERGAN INC For: Nov 30 Filed by: Dunsire Deborah (10K)

Form 4 ALLERGAN INC For: Nov 30 Filed by: GALLAGHER MICHAEL R (10K)

Form 4 ALLERGAN INC For: Nov 30 Filed by: BOYER HERBERT W PH D (10K)

Form 4 HERBERT GAVIN S For: Nov 10 (10K)

Form 4 EDWARDS JEFFREY L For: Nov 06 (10K)

Form 4 Diradoorian Raymond H For: Nov 05 (10K)

Form 4 GALLAGHER MICHAEL R For: Nov 03 (10K)

Form 4 INGRAM DOUGLAS S For: Nov 03 (10K)

Form 4 GALLAGHER MICHAEL R For: Oct 27 (10K)